Table 4.
change in DCIS detection | change in DCIS overdiagnosis |
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|
Model | A50-74 | B40-74 | B50-84 | A50-74 | B40-74 | B50-84 | A50-74 | B40-74 | B50-84 | |
D | 0.1 | 0.0 | 2.8 | 0.1 | 0.1 | 2.8 | 100% | N/A | 100% | |
E | 8.5 | 4.8 | 5.6 | 6.7 | 3.3 | 5.2 | 79% | 69% | 93% | |
GE | 3.2 | 3.6 | 6.3 | 0.4 | 1.2 | 3.0 | 13% | 33% | 48% | |
M | 13.6 | 5.0 | 5.5 | 13.7 | 5.1 | 5.6 | 101% | 102% | 102% | |
W | 14.0 | 2.4 | 9.7 | 7.1 | 1.5 | -1.1 | 51% | 63% | -11% |
A50-74: annual screening from age 50-74 years.
B40-74: biennial screening from age 40-74 years.
B50-84: biennial screening from age 50-84 years.
Model D: Dana-Farber Cancer Institute, Boston, Massachusetts. Model E: Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands. Model GE: Georgetown University Medical Center, Washington, DC, and Albert Einstein College of Medicine, Bronx, New York. Model M: MD Anderson Cancer Center, Houston, Texas. Model W: University of Wisconsin-Madison, Madison, Wisconsin, and Harvard Medical School, Boston, Massachusetts.